Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | bromodomain adjacent to zinc finger domain, 2B | Starlite/ChEMBL | No references |
Homo sapiens | muscleblind-like splicing regulator 1 | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.1287 | 0.1287 |
Loa Loa (eye worm) | hypothetical protein | 0.0085 | 0.4056 | 0.4056 |
Schistosoma mansoni | hypothetical protein | 0.0025 | 0.0271 | 0.0774 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.2479 | 0.2479 |
Loa Loa (eye worm) | PHD-finger family protein | 0.0025 | 0.0271 | 0.0271 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.1287 | 0.0737 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0027 | 0.0415 | 0.0415 |
Brugia malayi | Bromodomain containing protein | 0.0091 | 0.4379 | 0.4024 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0072 | 0.3223 | 0.3223 |
Echinococcus multilocularis | muscleblind protein 1 | 0.018 | 1 | 1 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.2479 | 0.2004 |
Echinococcus multilocularis | muscleblind protein | 0.018 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.1934 | 0.1934 |
Schistosoma mansoni | bromodomain containing protein | 0.0076 | 0.3493 | 1 |
Echinococcus multilocularis | zinc finger protein | 0.0024 | 0.0191 | 0.0191 |
Loa Loa (eye worm) | bromodomain containing protein | 0.0021 | 0.0046 | 0.0046 |
Brugia malayi | Bromodomain containing protein | 0.0046 | 0.1606 | 0.1076 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0027 | 0.0415 | 0.1188 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0027 | 0.0415 | 0.0415 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0043 | 0.1427 | 0.1427 |
Loa Loa (eye worm) | hypothetical protein | 0.018 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0046 | 0.1611 | 0.1611 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.2479 | 0.2479 |
Echinococcus granulosus | zinc finger protein | 0.0024 | 0.0191 | 0.0191 |
Schistosoma mansoni | zinc finger protein | 0.0024 | 0.0191 | 0.0546 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.2479 | 0.2004 |
Loa Loa (eye worm) | hypothetical protein | 0.0049 | 0.179 | 0.179 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.1287 | 0.3683 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0043 | 0.1427 | 0.1427 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0072 | 0.3223 | 0.3223 |
Echinococcus granulosus | muscleblind protein | 0.018 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.018 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.7079 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (functional) | 4.1475 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 7.9433 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 15.8489 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | 17.7828 uM | PubChem BioAssay. qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.